跳至主要内容
临床试验/NCT06715007
NCT06715007招募中不适用

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

The First Affiliated Hospital with Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2024年12月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
300
试验地点
1
主要终点
the impact of different antiplatelet agents on retinal vasculature.

研究概览

简要总结

Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).

详细描述

Cerebral small vessel disease (cSVD) is a common accompaniment of aging. It refers to a group of pathological processes with various etiologies that affect the small arteries, arterioles, venules, and capillaries of the brain. On neuroimaging, notably on magnetic resonance imaging (MRI), SVD has several visible signs, including recent small subcortical infarcts (i.e symptomatic cSVD in our study), lacunes of presumed vascular origin; white matter hyperintensities (WMH), perivascular spaces, cerebral microbleeds, cerebral microinfarcts and brain atrophy. SVD causes about a quarter of ischaemic strokes, is the main cause of vascular dementia, often occurs with Alzheimer's disease, contributing to about 50% of dementias worldwide. Although previous studies recommend BP control and antiplatelet therapy in symptomatic cSVD, secondary prevention strategies are mostly inferred from studies of ischemic stroke in general, the majority of which did not specifically investigate patients with symptomatic cSVD. In addition, long term dual antiplatelet therapy using clopidogrel and aspirin was shown to increase the risk of hemorrhage stroke in symptomatic cSVD, without any decrease in recurrent ischemic stroke.

Endothelial dysfunction plays an important part in cSVD. In addition to mild antiplatelet effects through the increase of cyclic adenosine monophosphate (cAMP), the phosphodiesterase (PDE) 3' inhibitor cilostazol is shown to be endothelial protective by several pathways, such as activation of endothelial nitric oxide (NO) synthase (NOS), regulation of endothelin-1. Isosorbide mononitrate (ISMN) is a NO donor, by augmenting the NO-cyclic guanosinemonophosphate phosphodiesterase-inhibitor pathway. Recent trial showed that the combined use of ISMN plus cilostazol was well tolerated and safe, and may reduce recurrent stroke and cognitive impairment after lacunar stroke.

Brain and retina possess numerous anatomical and functional similarities. Retinal capillary microvessels revealed by optical coherence tomography angiography (OCTA) have been found to be related to brain microvessels, reflecting the burden of cSVD. Retinal perfusion is also linked with cognitive function.

This cohort study will prospectively evaluate the effect of different antiplatelet agents on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
30 Years 至 79 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Patients with recent small subcortical infarct

Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),

干预措施: Clopidogrel (Drug)

Patients with recent small subcortical infarct

Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),

干预措施: Aspirin (Drug)

Patients with recent small subcortical infarct

Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),

干预措施: Cilostazol + Isosorbide Mononitrate (Drug)

Patients with Whiter matter changes

White matter hyperintensities with a 2-3 grading on Fazekas scale will be recruited. Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),

干预措施: Clopidogrel (Drug)

Patients with Whiter matter changes

White matter hyperintensities with a 2-3 grading on Fazekas scale will be recruited. Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),

干预措施: Aspirin (Drug)

Patients with Whiter matter changes

White matter hyperintensities with a 2-3 grading on Fazekas scale will be recruited. Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),

干预措施: Cilostazol + Isosorbide Mononitrate (Drug)

结局指标

主要结局

the impact of different antiplatelet agents on retinal vasculature.

时间窗: 6 months follow up

retinal vasculature will be assessed by optical coherence tomography and optical coherence tomography angiography.

次要结局

  • systemic or intracranial bleeding(systemic or intracranial bleeding will be assessed during 6 month follow-up.)
  • occurrence of ischemic stroke or transient ischemic attack(during 6 month follow-up)
  • Neurological function(Neurological function will be assessed at baseline, 1 week, 3 months and 6-month after recruitment.)
  • Brain MRI (magnetic resonance imaging)(Brain MR will be performed at baseline and at 6 months after recruitment)
  • Cognitive function(MoCA will be assessed at baseline and at 3 and 6 months after recruitment.)
  • modified Rankin Scale (mRS) score(modified Rankin Scale (mRS) score will be assessed at baseline and at 3 and 6 months after recruitment.)
  • Barthel index for activities of daily living(Barthel index will be assessed at baseline, 3 and 6 months after recruitment.)
  • Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)(UPDRS score will be evaluated at baseline and 3, 6 months after recruitment.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wang Zhaolu

Professor

The First Affiliated Hospital with Nanjing Medical University

研究点 (1)

Loading locations...

相似试验

Antiplatelet Therapy and Endothelial-stabilizing... | 临床试验